Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3577723 | 0.89 | MAOA (0.39) | MAPTMAOAMAOBSMN1; SMN2THRB | |
| SCHEMBL3575302 | 0.87 | THRB (0.39) | MAPTMAOAMAOBSMN1; SMN2THRB | |
| SCHEMBL4701387 | 0.86 | EPHX2 (0.36) | MAOB | |
| SCHEMBL4922812 | 0.84 | THRB (0.41) | MAPTMAOAMAOBSMN1; SMN2THRB | |
| SCHEMBL4918631 | 0.83 | EPHX2 (0.47) | ELANE | |
| SCHEMBL3570481 | 0.83 | UCHL1 (0.39) | MAPTMAOAMAOBSMN1; SMN2THRB | |
| SCHEMBL3571150 | 0.82 | MAPT (0.45) | MAPTATMELANELMNASMN1; SMN2 | |
| SCHEMBL3573660 | 0.82 | FAAH (0.40) | MAPTMAOAMAOBPTGS2 | |
| SCHEMBL3570957 | 0.82 | MAOA (0.43) | MAPTATMMAOAMAOBELANE | |
| SCHEMBL3569793 | 0.79 | GCK (0.40) | MAPTSMN1; SMN2THRBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705023-B2 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2010-04-27 | — | — | US | disclosed |
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-10-09 | — | — | US | disclosed |
| EP-1778632-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2007-12-13 | — | — | US | disclosed |
| EP-1778632-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2005123673-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | PTGS1, IDO1, PTGES | MAPT 3268/4885ATM 3830/4885MAOA 153/4885 |
| US-20080249091-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, ARG1 | MAPT 89/4885ATM 2865/4885MAOA 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.